Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Down 36.4% in September

Avalon GloboCare Corp. (NASDAQ:ALBT) saw a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 191,300 shares, a decrease of 36.4% from the September 15th total of 300,700 shares. Currently, 3.2% of the company’s stock are sold short. Based on an average daily trading volume, of 4,450,000 shares, the short-interest ratio is presently 0.0 days.

Avalon GloboCare Stock Up 2.0 %

Shares of ALBT stock opened at $0.22 on Monday. The firm has a market cap of $2.39 million, a PE ratio of -0.15 and a beta of 0.31. Avalon GloboCare has a 12 month low of $0.19 and a 12 month high of $1.44. The company’s fifty day simple moving average is $0.27 and its 200-day simple moving average is $0.34.

Avalon GloboCare (NASDAQ:ALBT) last released its earnings results on Monday, August 19th. The company reported ($0.19) earnings per share (EPS) for the quarter. The company had revenue of $0.33 million during the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.